Pathways' Pick of the Week: WHO's 2022 Global Atlas

article image
ARTICLE SUMMARY:

The World Health Organization has issued its 2022 “device atlas” report. Excerpted from Pathways' Picks November 30: Swiss-FDA Link, and More From The EU, US, and WHO.

About half of all countries have adopted some type of device nomenclature system, representing progress toward global harmonization, according to the World Health Organization’s 2022 Global Atlas of Medical Devices. The 600-plus-page document profiles 194 countries, listing basic health and technology innovation indicators and facts about whether each country has a national health policy, national authorities for device regulation and technology assessment, nomenclature adoption, and other relevant facts.  The report also includes a specific analysis of nomenclature adoption, finding that about 32% of countries use either the European Medical Device Nomenclature, the Universal Medical Device Nomenclature System, or the Global Medical Device Nomenclature. Another 18% employ nationally developed systems and 5% report using multiple systems. The remaining 45% did not report use of any system. “Several efforts are currently in place to harmonize not only the heterogeneous regulatory framework worldwide, but more specifically an international nomenclature system,” WHO notes in the report.

  Trial MyStrategist.com and unlock 7-days of exclusive  subscriber-only access to the medical device industry's most trusted strategic publications: MedTech Strategist & Market Pathways. For more information on our demographics and current readership  click here.

 

×



Articles from David Filmore:

Regulatory & Reimbursement

Navigating De Novos: Engage, Respond, and Consider Postmarket Controls

Less than half of devices that pursued FDA’s De Novo classification as a route to market in recent years have had success as firms struggle to prove effectiveness for their novel low-to-moderate risk technologies. Advice from a CDRH official and expert consultant on the best ways for companies to build rapport and gain buy-in from reviewers and to take advantage of opportunities to win the benefit-risk balance with the help of postmarket planning.

Read Article